

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61K 31/70, 9/20, 9/28</b>		A1	(11) International Publication Number: <b>WO 00/48607</b> (43) International Publication Date: 24 August 2000 (24.08.00)
<p>(21) International Application Number: <b>PCT/SI00/00002</b></p> <p>(22) International Filing Date: 17 February 2000 (17.02.00)</p> <p>(30) Priority Data: P-9900039 19 February 1999 (19.02.99) SI</p> <p>(71) Applicant (<i>for all designated States except US</i>): LEK, TO-VARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV, D.D. [SI/SI]; Verovškova 57, 1526 Ljubljana (SI).</p> <p>(72) Inventors; and            (75) Inventors/Applicants (<i>for US only</i>): FERČEJ TEMELJOTOV, Darja [SI/SI]; Avčinova 10, 1000 Ljubljana (SI). MOHAR, Milojka [SI/SI]; Gostičeva 9, 1230 Domžale (SI). SALOBIR, Mateja [SI/SI]; Ulica 28. maja 9, 1000 Ljubljana (SI). REBIČ, Ljubomira, Barbara [SI/SI]; Dergomaška 50, 1000 Ljubljana (SI). OPRESNIK, Marko [SI/SI]; Ulica bratov Babnik 42, 1000 Ljubljana (SI).</p> <p>(74) Agent: PATENTNA PISARNA, D.O.O; Copova 14, P.O. Box 1725, 1001 Ljubljana (SI).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>With international search report.            Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: DIRECTLY COMPRESSIBLE MATRIX FOR CONTROLLED RELEASE OF SINGLE DAILY DOSES OF CLARITHROMYCIN</p> <p>(57) Abstract</p> <p>The invention refers to an improved pharmaceutical formulation for controlled release of clarithromycin or its derivatives, enabled by a novel combined matrix consisting of a fatty and a hydrophilic component, whereto also a surfactant and a pH-modulator may be added when an additional influence on the release profile of the active substance is desired.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## DIRECTLY COMPRESSIBLE MATRIX FOR CONTROLLED RELEASE OF SINGLE DAILY DOSES OF CLARITHROMYCIN

### *Technical Field*

(IPC: C 07 G 11/00, A 61 J 3/10)

The present invention belongs to the field of pharmaceutical technology and deals with the macrolide antibiotic clarithromycin and its derivatives.

In the narrow sense the present invention deals with a novel peroral pharmaceutical formulation for controlled release of clarithromycin or its derivatives, enabled by a novel combined matrix consisting of a fatty and a hydrophilic component, whereto a surfactant and a pH modulator can be added when an additional influence on the release profile of the active substance is desired.

### *Background of the Invention*

Clarithromycin is a slightly alkaline, practically water-insoluble and acid-sensitive macrolide antibiotic. Its solubility decreases with increased temperature and increased pH. A daily dose amounting to 500 mg has to be embedded in a relatively small matrix since a tablet should not be too large to swallow, thus leaving only a relatively narrow space for optimization of biopharmaceutical and physical-technological properties of a formulation. Consequently, in the preparation of a 24-hour tablet we face the problem of a high dose of a poorly soluble active substance and at the same time the need to ensure a repeatable and pH-independent release of clarithromycin according to a specific selected optimal time schedule.

The commercially available peroral formulation of clarithromycin with extended release contains an alginate matrix, which is known for its high dependence of the release of the active substance on the pH, whose preparation technology includes, inter alia, time-consuming and expensive processes of wet granulation, drying and

sieving and which frequently also exhibits non-repeatable dissolution profiles between different series and a slowing down of the dissolution due to aging.

Thus, the present invention is based on a need to find a simple, efficient and pH-independent formulation which will repeatably release clarithromycin over 24 hours, thereby minimizing the subjective influences with each single patient. The release rate has to ensure optimal concentrations of the active substance in blood in order to achieve therapeutic effects over a longer time period.

#### *Prior Art*

Clarithromycin is a semisynthetic antibiotic formed by methylation of erythromycin on a lactone position of C6. Its synthesis was described in US patents 4,331,803 and 4,672,109. It acts on Gram-positive bacteria and is used clinically due to the wide spectrum of antimicrobial activity. On the market it is present in the form of lacquered tablets, a suspension and extended-release tablets.

Various (per)oral formulations with clarithromycin are also described in the following patent literature:

JP patent 85/163,823 describes an oral drug containing clarithromycin and citric acid increasing the absorption of the antibiotic in the digestive tract, disintegrants, carriers and lubricants.

Withdrawn EP patent application No. 277,042 describes an oral pharmaceutical formulation with improved taste, with a coating made of special polymers (especially polyvinylacetal diethylaminoacetate - AEA) soluble in gastric juice and with average particle diameters under 60 µm.

US patent 4,808,411 describes a formulation with erythromycin or its derivatives and a carbomer, optionally in the form of particles of an ionic complex, coated with a polymer, whereat the particles can be suspended in a liquid carrier.

JP patent 89/42,625 describes the preparation of film-coated microgranules of a drug with sustained action, which, in addition to clarithromycin, also contain AEA and water.

Withdrawn EP patent application No. 302,370 and WO patent application No. 90/08,537 describe improved (per)oral formulations (oily solution, suspension, emulsion) of erythromycin and its derivatives for filling into soft gelatin capsules with N-methyl-pyrrolidone.

EP patent 420,992 describes a process for producing a taste-masked oral formulation comprising spraying a suspension of a drug into a cold aqueous solution of AEA.

US patent 5,017,383 describes a method of producing a finely coated pharmaceutical formulation comprising mixing frozen particles of a liquid medium with a drug and a coating in the form of a fine powder adhering to the surface of the particles.

US patents 5,599,556 and 5,609,909 describe the taste-masking of encapsulated clarithromycin particles with prolamine coatings prior to the preparation of a suspension.

WO patent application No. 96/34,628 describes a formulation with masked taste for oral administration (especially a dry syrup), containing an unpleasantly tasting drug, a high polymer soluble in the stomach (preferably AEA or Eudragit E) and a monoglyceride having a low melting point (preferably glyceryl monostearate) in a stable  $\beta$ -crystal form (transfer from meta stable  $\alpha$ -form by means of shaking at an elevated temperature) and a method for masking the taste.

WO patent application No. 97/16,174 describes a process for water-granulation of a macrolide antibiotic with a carbomer (acrylic polymer).

US patent 5,705,190 describes a solid oral pharmaceutical formulation with controlled release containing a drug poorly soluble in water, a water-soluble alginate salt, a complex salt of alginic acid with a metal cation and an organic carboxylic acid facilitating the dissolution of the drug.

US patent 5,707,646 describes a formulation for oral administration (especially dry syrup) containing an unpleasantly tasting drug, a functional polymer (preferably AEA and/or Eudragit E) in a substance having a melting point at 40-120°C, a sugar alcohol (e.g. sorbitol) and a basic oxide (preferably MgO).

WO patent application No. 98/46,239 describes a pharmaceutical formulation with extended action containing an erythromycin derivative and a hydrophilic water-soluble polymer, showing, at oral administration, an improved taste profile and fewer gastrointestinal side effects in comparison to the usual formulation, and the preparation technology comprises, inter alia, processes of wet granulation, drying, sieving and milling.

Thus, in patent and other literature from this field there can be found numerous publications describing the composition and the preparation of various formulations with clarithromycin, but no literature source has been found that would describe such a simple process for the preparation of a clarithromycin formulation with controlled release, enabling a selected and pH-independent release profile of the active substance over 24 hours.

#### *Description of Novel Solution with Examples*

The object of the invention is a novel matrix for a controlled release of clarithromycin or its derivatives, which contains a mixture of a fatty, water-insoluble component

being the main carrier of sustained release, and of a hydrophilic component that in an aqueous medium swells, gels or thickens and thereby forms a viscous layer through which the solubilized, dissolved active substance diffuses, thus influencing the structure and consistency of the whole matrix.

To this basic matrix there may be added a wetting agent, a surfactant which softens the matrix and binds together both types of components and contributes to an easier solubilization of the active substance. The result is a matrix system which by means of a mixed mechanism of tablet erosion and diffusion releases the solubilized and/or dissolved active substance through the viscous layer.

In order to additionally influence the release profile of the active substance, to the matrix there may optionally be added a pH modulator, which is an alkaline substance, e.g. a phosphate buffer, influencing the portion of the released active substance in the stomach in relation to the intestine or decreasing the influence of the current level of acidity in any particular part of the digestive tract.

Among fatty components to be used in the embodiments of the present invention, the suitable ones are triglycerides of higher saturated fatty acids such as palmitic acid, stearic acid and behenic acid, preferably glyceryl behenate, hydrogenated oils (e.g. vegetable oils or castor oil), carnauba wax and similar. The content of the fatty component of the matrix amounts to about 10-36 % of the mass of a tablet.

Glyceryl behenate is a lipid substance, most frequently used as a lubricant, with an additional favourable property that in higher concentrations it sustains the release of active substances. Chemically, it is a mixture of glyceryl esters of behenic/docozanoic acid ( $C_{22}$ ) with a low content of mono-behenate and a melting point of 69-74°C.

As the hydrophilic component there are selected substances which increase the viscosity of the micro-environment, are suspendable, stabilize the current viscous layer and may also have the ability to soften the fatty components of the matrix.

Suitable substances are alkyl-substituted cellulose ethers, preferably hydroxypropyl methylcellulose (HPMC), more preferably HPMC with low viscosity, fatty alcohols (e.g. cetyl, stearyl, cetostearyl alcohols), polysaccharides (e.g. xanthan gum, guar gum, acacia), adsorbents with a large specific surface (e.g. Mg-Al-silicates) and the like. The content of the hydrophilic component of the matrix amounts to about 5-18 % of the mass of a tablet.

HPMC is a cellulose ether, usually used for increasing the viscosity of the environment, but simultaneously it also influences the release rate of active substances. Used were low-viscous types of HPMC having viscosities (nominally for a 2 % aqueous solution at 20°C) up to about 40 cP and  $M_n$  up to about 20000 (determined by the method of osmotic pressures).

It has been found that by combining glyceryl behenate and HPMC there was obtained an exceptionally effective matrix for sustaining and controlling the release of the active substance, since in contact with an aqueous medium (also in the stomach) it swells and thereby loosens the lipid (glyceryl behenate) structure and makes possible a release of clarithromycin by diffusion through the viscous layer at a simultaneous erosion of the matrix i.e the tablet. The ratio between the lipophilic and the hydrophilic components may be between 2 : 1 and 10 : 1.

Among surfactants, anionic ones e.g. sodium docusate, sodium lauryl sulfate, and non-ionic ones can be used. The content of the surfactant amounts to about 0.5-3% of the mass of a tablet.

Sodium docusate is an anionic surfactant which in the given combination contributes to a more uniform wetting of the lipid structure and thereby facilitates the hydration and the swelling of the matrix and makes possible a repeatable diffusion of clarithromycin from the matrix.

Tablets with clarithromycin can also be lacquered, e.g. with a suspension based on a mixture of HPMC and hydroxypropyl cellulose (HPC), according to a conventional

process or the release profile of clarithromycin is modulated by the application of an acid-resistant coating such as HPMC-phthalate.

An excellent property of the formulation of the present invention in comparison to prior art is a simple preparation technology since all ingredients are, at room temperature, just homogeneously mixed together, sieved and directly compressed into tablets, therefore no water or any other solvents are necessary.

An important technological advantage of the formulation of the present invention is also the fact that there is no need for additional lubricants, since glyceryl behenate itself, as the carrier of release control, has good lubricating properties.

Dissolution rates of clarithromycin *in vitro* from two matrix samples with controlled release over 24 hours were measured at the temperature of 37°C, during the first hour at pH = 3.0 and during the subsequent 23 hours at pH 6.8. They are shown in Figs. 1 and 2.

The invention is explained but in no way limited by the following examples.

***Example 1***

Composition of one tablet:	clarithromycin	500 mg
	glyceryl behenate (Compritol 888)	350 mg
	HPMC (E50-LV P)	150 mg
	lactose	150 mg

Dissolution test:

Dissolution profile is shown in Fig. 1.

***Example 2***

The composition was the same as in Example 1 only that instead of 34.5 g of lactose the same quantity of Na-docusate was used.

***Example 3***

Composition of one tablet:	clarithromycin	500	mg
	glyceryl behenate (Compritol 888)	350	mg
	HPMC (E50-LV P)	150	mg
	lactose	131.905	mg
	NaH <sub>2</sub> PO <sub>4</sub>	49.538	mg
	Na <sub>2</sub> HPO <sub>4</sub>	2.607	mg
	Na-docusate	5.95	mg

Dissolution test:

Dissolution profile is shown in Fig. 2.

*Example 4*

Composition of one tablet:	clarithromycin	500 mg
	glyceryl behenate (Compritol 888)	350 mg
	HPMC (E15-LV P)	150 mg
	polyvinyl pyrrolidone (K 25)	60 mg
	microcrystalline cellulose	40 mg
	stearic acid	15 mg
	SiO <sub>2</sub> (Aerosil 200)	5 mg
	talc	5 mg
	Ca-stearate	25 mg

*Example 5*

Composition of one tablet:	clarithromycin	500 mg
	glyceryl behenate (Compritol 888)	350 mg
	HPMC (E50-LV P)	150 mg
	polyvinyl pyrrolidone (K 25)	60 mg
	microcrystalline cellulose	40 mg
	stearic acid	15 mg
	SiO <sub>2</sub> (Aerosil 200)	5 mg
	talc	5 mg
	Ca-stearate	25 mg

*Example 6*

The composition of a tablet was the same as in Examples 1-5 only that on the tablet also an acid-resistant coating with the following composition was applied:

HPMC-phthalate	28.75 mg
triethyl citrate	2.875 mg
yellow pigment (Fe-oxide)	0.822 mg
TiO <sub>2</sub>	0.514 mg
talc	4.039 mg

**Claims**

1. A pharmaceutical formulation for peroral single daily application, characterized in that it contains clarithromycin or its derivatives and a mixture of a fatty and a hydrophilic component.
2. A pharmaceutical formulation according to claim 1, characterized in that in addition to the given components it contains a surfactant.
3. A pharmaceutical formulation according to claim 1, characterized in that in addition to the given components it contains a pH modulator.
4. A pharmaceutical formulation according to claim 1, characterized in that in addition to the given components it contains other pharmaceutically acceptable additives.
5. A pharmaceutical formulation according to claim 1, characterized in that the fatty component is glyceryl behenate.
6. A pharmaceutical formulation according to claim 1, characterized in that the hydrophilic component is hydroxypropyl methylcellulose of low viscosity.
7. A pharmaceutical formulation according to claim 6, characterized in that hydroxypropyl methylcellulose has a viscosity of about 15 cP.
8. A pharmaceutical formulation according to claim 2, characterized in that the surfactant is sodium docusate.
9. A pharmaceutical formulation according to claim 3, characterized in that the pH modulator is a phosphate buffer.

10. A pharmaceutical formulation according to claim 1, characterized in that it is in the form of a tablet.
11. A pharmaceutical formulation according to claim 10, characterized in that the tablet is lacquered.
12. A pharmaceutical formulation according to claim 10, characterized in that on the tablet an acid-resistant coating is applied.
13. A process for the preparation of a pharmaceutical formulation according to claim 1, characterized in that it comprises homogeneous mixing, sieving and direct compressing into tablets without use of solvents.
14. A pharmaceutical formulation for peroral single daily application, characterized in that it is prepared according to the process according to claim 13.
15. A pharmaceutical formulation according to claims 1 to 12 for use in the treatment and prophylaxis of bacterial infections.

1/2




Fig. 1




Fig. 2

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/SI 00/00002

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/70 A61K9/20 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 95 22319 A (ABBOT LABORATORIES) 24 August 1995 (1995-08-24)</p> <p>page 8; example 1B page 5, line 31 - line 35</p>	1,4,5, 10,11, 13-15

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 June 2000

Date of mailing of the international search report

11/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/SI 00/00002

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9522319 A	24-08-1995	EP 0744941 A	JP 9509176 T	04-12-1996 16-09-1997